trending Market Intelligence /marketintelligence/en/news-insights/trending/N93WWTIfoL7TuxoZIlc5LA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UroGen Pharma starts rolling US FDA submission for bladder cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


UroGen Pharma starts rolling US FDA submission for bladder cancer drug

Israel's UroGen Pharma Ltd. started the rolling submission of a new drug application to the U.S. Food and Drug Administration for cancer therapy UGN-101.

UGN-101, also known as mitomycin gel, is intended to treat low-grade upper tract urothelial cancer, a type of bladder cancer.

The drug's application is supported by data from a late-stage trial, called Olympus, topline results of which is expected in January 2019. The company anticipates to complete the rolling submission by mid-2019, and to receive approval within the same year.

UroGen Pharma said UGN-101 would provide a nonsurgical treatment option for urothelial cancer, potentially eliminating the need for repetitive surgical intervention and kidney removal.

The FDA has granted UGN-101 orphan-drug, fast-track and breakthrough-therapy designations.